Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients
Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients
复制标题
DOI：
10.1007/s00262-009-0695-6
复制
发表时间：
2009-11-01
影响因子：
5.8
通讯作者：
Okuno, Kiyotaka
中科院分区：
文献类型：
--
作者：
Hattori, Takashi;Mine, Takashi;Okuno, Kiyotaka
为了研究个性化肽疫苗接种联合口服UFT和UZEL治疗转移性结直肠癌（mCRC）的安全性和免疫应答，本研究招募了14名患者。基于每个患者中肽特异性细胞毒性T淋巴细胞前体和IgG的存在来确定肽。每周皮下给予最多4种肽，UFT（300 mg/m2/天）和UZEL（75 mg/天），持续4周，然后休息1周。该治疗耐受性良好，尽管1例患者的疫苗接种部位出现3级皮肤反应。在第十次疫苗接种后，分别在十名受试患者中的九名或十名受试患者中的八名中观察到肽特异性干扰素γ产生或肽特异性IgG增加。IgG应答与总生存期密切相关（P = 0.0215）。本疗法的安全性和免疫反应性表明，这种联合治疗对mCRC患者具有临床益处，值得进一步试验。
To investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of UFT and UZEL for metastatic colorectal carcinoma (mCRC), fourteen patients were enrolled in the present study. Peptides were determined based on the presence of peptide-specific cytotoxic T lymphocyte precursors and IgG in each patient. A maximum of four peptides were subcutaneously administered weekly with UFT (300 mg/m(2) day(-1)) and UZEL (75 mg/day) for 4 weeks, followed by 1 week of rest. This therapy was well-tolerated although there was a grade-3 skin reaction at the vaccination site in one patient. An increase in peptide-specific interferon-gamma production or peptide-specific IgG after the tenth vaccination was observed in nine of ten or eight of ten patients tested, respectively. IgG responses were well correlated with overall survival (P = 0.0215). The safety and immunological responsiveness of the present therapy suggest that this combination would be of clinical benefit for mCRC patients, and further trials are merited.